Palisade Bio (PALI) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Palisade Bio (PALI) has outperformed Protara Therapeutics (TARA) over the past year, losing 60.6% versus a loss of 68.6%. Over five years, TARA leads with a -67.8% price change compared with -100.0% for PALI. Palisade Bio is the larger company by market cap ($150.7 million vs $140.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PALI | TARA |
|---|---|---|
| Share price | $0.8399 | $2.28 |
| Market cap | $150.74M | $140.38M |
| 1-day change | -9.24% | -5.00% |
| YTD return | -64.26% | -57.22% |
| 1-year return | -60.57% | -68.60% |
| 5-year return | -99.95% | -67.80% |
| P/E ratio (TTM) | 0.91 | — |
| EPS (TTM) | $0.92 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-16.78M | $-57.44M |
| 52-week high | $2.86 | $7.82 |
| 52-week low | $0.8381 | $2.09 |
| Distance from 52-week high | -70.63% | -70.84% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +935.84% | +1010.96% |
| Average volume | 3.19M | 1.07M |
| Shares outstanding | 179.28M | 61.57M |
| Employees | 14 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
PALI vs TARA FAQ
Which is bigger, Palisade Bio or Protara Therapeutics?
Palisade Bio (PALI) is larger, with a market capitalization of $150.74M compared with $140.38M for Protara Therapeutics (TARA).
Which stock has performed better over the past year, PALI or TARA?
PALI returned -60.57% over the past 12 months, compared with -68.60% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Palisade Bio and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.